



## LETTERS TO THE EDITOR

# Differences in the Epidemiology of Rare *EGFR* Mutations in Different Populations



## In Response:

We thank Elghissassi et al. for their comment on our study.<sup>1</sup> This is a great opportunity to further discuss the differences in the epidemiology of rare epidermal growth factor receptor gene (*EGFR*) mutations in different patient populations.

The complete coverage of exons 18 to 21 and the *EGFR* analysis in patients with Kirsten rat sarcoma viral oncogene homolog (*KRAS*) mutations—as we all agree—could very well be one reason for the increased rate of rare *EGFR* mutations. Importantly, it seems that smoking status can also have a great—and indeed patient population-dependent—impact on the rate of rare *EGFR* mutations. Unfortunately, in Hungary as well as in our patient cohort, the number of current smokers is very high, which could lead to enrichment for rare *EGFR* mutations. Interestingly, unlike in white cohorts, the rare *EGFR* mutations in Asian populations do not seem to be associated with smoking. Notably, the findings of Errihani et al. suggest that the epidemiology of such mutations in Morocco has greater resemblance to that in the Asian population than to that in white study cohorts.<sup>2</sup>

We cannot emphasize enough that the lack of identical methods makes side-by-side comparison of the different studies very difficult. A number of commercial mutation analysis methods provide very high sensitivity, but only for a preselected set of molecular alterations that might enrich for classical *EGFR* mutations.<sup>3</sup> In contrast, direct (Sanger) sequencing has a lower sensitivity but can identify novel mutations. Indeed, a number of rare mutations described in our study were reported in lung adenocarcinoma for the first time. Of note, we cannot rule out that some of

the mutations might have been artefacts because this possibility has been discussed in a previous exchange of comments.<sup>4,5</sup>

One of the major findings of our study is that the absolute number of rare *EGFR* mutations in certain patient populations can be rather high, and thus, their clinical relevance needs to be studied further. Moreover, the term *rare EGFR mutation* describes a very heterogeneous group of molecular alterations, and as a result, the clinical relevance of each individual mutation needs to be evaluated separately. Therefore, reporting the clinical relevance and epidemiology of all *EGFR* mutations for different patient populations will lead to more accurate and evidence-based therapy decisions in the future.

**Zoltan Lohinai, MD**

National Koranyi Institute of Pulmonology  
Budapest, Hungary  
Translational Thoracic Oncology Laboratory  
Division of Thoracic Surgery, Department of Surgery  
Comprehensive Cancer Center  
Medical University of Vienna, Austria  
Department of Thoracic Surgery  
National Institute of Oncology-Semmelweis University  
Budapest, Hungary

**Gyula Ostoros, MD, PhD**

National Koranyi Institute of Pulmonology  
Budapest, Hungary

**Judit Moldvay, MD, PhD**

National Koranyi Institute of Pulmonology  
Budapest, Hungary

**Balazs Dome, MD, PhD**

National Koranyi Institute of Pulmonology  
Budapest, Hungary  
Translational Thoracic Oncology Laboratory  
Division of Thoracic Surgery, Department of Surgery  
Comprehensive Cancer Center  
Medical University of Vienna, Austria  
Department of Thoracic Surgery  
National Institute of Oncology-Semmelweis University  
Budapest, Hungary

**Balazs Hegedus, PhD**

Translational Thoracic Oncology Laboratory  
Division of Thoracic Surgery, Department of Surgery  
Comprehensive Cancer Center  
Medical University of Vienna, Austria

**Disclosure:** The authors declare no conflict of interest.

Address for correspondence: Balazs Dome, MD, PhD, Division of Thoracic Surgery, Medical University of Vienna, Waehringer Guertel 18-20, A-1090, Vienna, Austria. E-mail: [balazs.dome@meduniwien.ac.at](mailto:balazs.dome@meduniwien.ac.at)

© 2015 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

ISSN: 1556-0864

<http://dx.doi.org/10.1016/j.jtho.2015.09.003>

2nd Department of Pathology, Semmelweis University  
Budapest, Hungary  
Molecular Oncology Research Group  
Hungarian Academy of Sciences-Semmelweis University  
Budapest, Hungary

## References

1. Lohinai Z, Hoda MA, Fabian K, et al. Distinct epidemiology and clinical consequence of classic versus rare *EGFR* mutations in lung adenocarcinoma. *J Thorac Oncol*. 2015;10:738-746.
2. Elghissassi I, Errihani H. Spectrum of *EGFR* mutation in lung adenocarcinoma in Morocco. *J Thorac Oncol*. 2013;8:e115-e116.
3. Lopez-Rios F, Angulo B, Gomez B, et al. Comparison of molecular testing methods for the detection of *EGFR* mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. *J Clin Pathol*. 2013;66:381-385.
4. Domingues PM, Montella T, Baldotto C. Rare versus artifactual *EGFR* mutations. *J Thorac Oncol*. 2015;10:e79-e80.
5. Lohinai Z, Ostoros G, Moldvay J, Dome B, Hegedus B. Reply to Rare versus Artifactual *EGFR* Mutations. *J Thorac Oncol*. 2015;10:e80-e81.